PMID- 19721814
OWN - NLM
STAT- PubMed-not-MEDLINE
DCOM- 20100618
LR  - 20211028
IS  - 1570-159X (Print)
IS  - 1875-6190 (Electronic)
IS  - 1570-159X (Linking)
VI  - 7
IP  - 1
DP  - 2009 Mar
TI  - Implication of complement system and its regulators in Alzheimer's disease.
PG  - 1-8
LID - 10.2174/157015909787602805 [doi]
AB  - Alzheimer's disease (AD) is an age-related neurodegenerative disease that affects 
      approximately 24 million people worldwide. A number of different risk factors 
      have been implicated in AD, however, neuritic (amyloid) plaques are considered as 
      one of the defining risk factors and pathological hallmarks of the disease. 
      Complement proteins are integral components of amyloid plaques and cerebral 
      vascular amyloid in Alzheimer brains. They can be found at the earliest stages of 
      amyloid deposition and their activation coincides with the clinical expression of 
      Alzheimer's dementia. This review emphasizes on the dual key roles of complement 
      system and complement regulators (CRegs) in disease pathology and progression. 
      The particular focus of this review is on currently evolving strategies for 
      design of complement inhibitors that might aid therapy by restoring the fine 
      balance between activated components of complement system, thus improving the 
      cognitive performance of patients. This review discusses these issues with a view 
      to inspiring the development of new agents that could be useful for the treatment 
      of AD.
FAU - Kolev, Martin V
AU  - Kolev MV
AD  - Department of Medical Biochemistry and Immunology, School of Medicine, Heath 
      Park, Cardiff University, Cardiff CF14 4XN, UK.
FAU - Ruseva, Marieta M
AU  - Ruseva MM
FAU - Harris, Claire L
AU  - Harris CL
FAU - Morgan, B Paul
AU  - Morgan BP
FAU - Donev, Rossen M
AU  - Donev RM
LA  - eng
GR  - G0700102/MRC_/Medical Research Council/United Kingdom
PT  - Journal Article
PL  - United Arab Emirates
TA  - Curr Neuropharmacol
JT  - Current neuropharmacology
JID - 101157239
PMC - PMC2724661
OTO - NOTNLM
OT  - Alzheimer's disease
OT  - CD59
OT  - complement
OT  - complement regulators
OT  - complement therapeutics.
OT  - inflammation
OT  - neurodegeneration
OT  - beta-amyloid peptide
EDAT- 2009/09/02 06:00
MHDA- 2009/09/02 06:01
PMCR- 2009/09/01
CRDT- 2009/09/02 09:00
PHST- 2008/08/25 00:00 [received]
PHST- 2008/12/01 00:00 [revised]
PHST- 2008/12/08 00:00 [accepted]
PHST- 2009/09/02 09:00 [entrez]
PHST- 2009/09/02 06:00 [pubmed]
PHST- 2009/09/02 06:01 [medline]
PHST- 2009/09/01 00:00 [pmc-release]
AID - CN-7-1 [pii]
AID - 10.2174/157015909787602805 [doi]
PST - ppublish
SO  - Curr Neuropharmacol. 2009 Mar;7(1):1-8. doi: 10.2174/157015909787602805.